BibTex RIS Cite

-

Year 2005, Volume: 18 Issue: 2, 53 - 58, 29.06.2015

Abstract

-

References

  • 1. Haier J, Nasralla M, Nicolson GL. Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg 2000; 231: 11-24.
  • 2. Steele GD, Mayer RJ. Adenocarcinoma of the colon and rectum.In: Shackelford’s surgery of the alimentary tract. 4th ed. Philadelphia: WB Saunders,1996:124-139.
  • 3. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR,FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000; 86: 174-181.
  • 4. Compton CC.Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum excluding carcinoid tumors, lymphomas, sarcomas,and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124:1016-1025.
  • 5. Burdy G ,Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-688.
  • 6. Folkman J. Tumor angiogenesis Therapeutic implications. N Eng J Med 1971;285:1182-1186.
  • 7. Güllüoğlu M, Dizdaroğlu F. Tümör anjiogenezi, Ulusal Cerrahi Dergisi 2000; 16:279-290.
  • 8. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 1994; 37:921-926.
  • 9. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node negative colon cancer. Ann Surg 1995; 222:695-699.
  • 10. Ishigami SI, Arii S, Furutani M, et al. Predictive value of VEGF in metastases and poor prognosis of human colorectal cancer. Brit J Cancer 1998; 78:1379-1384.
  • 11. Cascinu S, Staccioli MP, Gasparini G, et al.. Expression of VEGF can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6:2803-2807.
  • 12. Oh-e H, Tanaka S, Kitadai Y, Shimamoto F, Yoshihara M, Haruma K. Angiogenesis at the site of deepest penetration predicts lymph node metastasis of submucosal colorectal cancer. Dis Colon Rectum 2001; 44:1229-1236.
  • 13. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of VEGF expression in colorectal cancer patients. Eur J Cancer 2000; 36:748-753.
  • 14. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human antiVEGF in patients with advanced cancer. J Clin Oncol 2001;19: 843-850.
  • 15. Banner BF, Whitehouse R, Baker SP, Swanson RS. Tumor anjiogenez in stage II colorectal carcinoma. Am J Clin Pathol 1998;109: 733-737.
  • 16. Tokunaga T, Oshika Y, Abe Y, et al.. Vascular endothelial growth factor mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Brit J Cancer 1998;77:998- 1002.
  • 17. Konno H, Tanaka T, Baba M, et al. Quantitative analysis of vasculer endothelial growth factor in colon cancer. Eur Surg Res 1998; 30;273-278.
  • 18. Langlois N, Walker LG, Smith I, Skinner L, Eremin O, Heys SD. Expression of growth factor receptors is not a prognostic indicator in young patients with colo-rectal cancer. J Roy Coll Surg Edin 1997; 42:98-101.
  • 19. Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 1983; 198:743-752.
  • 20. Gervaz P, Bouzourene H, Cerottini JP, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001;44:364-373.
  • 21. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators in colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986;57:1866-1870.
  • 22. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vasculer endothelial growth factor as prognostic factors in node negative colon cancer. Arch Surg 1997;132: 541-546.
  • 23. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O'Malley FP. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996; 20:1260- 1265.

KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ

Year 2005, Volume: 18 Issue: 2, 53 - 58, 29.06.2015

Abstract

Amaç: Adjuvan tedaviden fayda görebilecek kolorektal kanserli hastaları seçebilmek için histopatolojik evrelemeye ek olarak yeni
prognostik belirteçlere ihtiyaç duyulmaktadır. Kolorektal kanserlerde ise anjiogenezin prognoz üzerine etkisi halen tartışmalıdır.
Yöntem: Modifiye-Astler-Coller Evre A-B olarak histopatolojik tanı almış 119 hasta belirlenmiş ve düzenli takipleri olan, 41 hasta
çalışmaya alınmıştır. Bu hastaların 16 tanesinde lokal rekürrens veya uzak metastaz tespit edilmiştir. VEBF ekspresyonu anti-rabbit
immunoglobulin boyaması yöntemiyle belirlenmiştir.
Bulgular: VEBF ekspresyonu negatif olan grupta 5 yıllık yaşam %83.33, VEBF ekspresyonu pozitif olan grupta ise 5 yıllık yaşam
%82,13 olarak bulunmuştur. VEBF ekspresyonu ile tümör yerleşimi, tümör derecesi, pT evresi, angio-nöral-lenfatik invazyon, lokal nüks
ve uzak metastaz ve 5 yıllık sağ kalım arasında anlamlı bir bağlantı tespit edilememiştir. Ancak kitle dışı klinik bulgular ile başvuran
hastalarda, sağ kalım açısından anlamlı fark bulunmuştur (p=0.003).
Sonuç: Bu çalışma sonucuna göre evre A-B kolo-rektal kanserlerde immünhistokimyasal yöntemle anjiogenez belirlenmesinin
prognostik önemi gösterilememiştir.

References

  • 1. Haier J, Nasralla M, Nicolson GL. Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg 2000; 231: 11-24.
  • 2. Steele GD, Mayer RJ. Adenocarcinoma of the colon and rectum.In: Shackelford’s surgery of the alimentary tract. 4th ed. Philadelphia: WB Saunders,1996:124-139.
  • 3. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR,FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000; 86: 174-181.
  • 4. Compton CC.Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum excluding carcinoid tumors, lymphomas, sarcomas,and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124:1016-1025.
  • 5. Burdy G ,Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-688.
  • 6. Folkman J. Tumor angiogenesis Therapeutic implications. N Eng J Med 1971;285:1182-1186.
  • 7. Güllüoğlu M, Dizdaroğlu F. Tümör anjiogenezi, Ulusal Cerrahi Dergisi 2000; 16:279-290.
  • 8. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 1994; 37:921-926.
  • 9. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node negative colon cancer. Ann Surg 1995; 222:695-699.
  • 10. Ishigami SI, Arii S, Furutani M, et al. Predictive value of VEGF in metastases and poor prognosis of human colorectal cancer. Brit J Cancer 1998; 78:1379-1384.
  • 11. Cascinu S, Staccioli MP, Gasparini G, et al.. Expression of VEGF can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6:2803-2807.
  • 12. Oh-e H, Tanaka S, Kitadai Y, Shimamoto F, Yoshihara M, Haruma K. Angiogenesis at the site of deepest penetration predicts lymph node metastasis of submucosal colorectal cancer. Dis Colon Rectum 2001; 44:1229-1236.
  • 13. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of VEGF expression in colorectal cancer patients. Eur J Cancer 2000; 36:748-753.
  • 14. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human antiVEGF in patients with advanced cancer. J Clin Oncol 2001;19: 843-850.
  • 15. Banner BF, Whitehouse R, Baker SP, Swanson RS. Tumor anjiogenez in stage II colorectal carcinoma. Am J Clin Pathol 1998;109: 733-737.
  • 16. Tokunaga T, Oshika Y, Abe Y, et al.. Vascular endothelial growth factor mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Brit J Cancer 1998;77:998- 1002.
  • 17. Konno H, Tanaka T, Baba M, et al. Quantitative analysis of vasculer endothelial growth factor in colon cancer. Eur Surg Res 1998; 30;273-278.
  • 18. Langlois N, Walker LG, Smith I, Skinner L, Eremin O, Heys SD. Expression of growth factor receptors is not a prognostic indicator in young patients with colo-rectal cancer. J Roy Coll Surg Edin 1997; 42:98-101.
  • 19. Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 1983; 198:743-752.
  • 20. Gervaz P, Bouzourene H, Cerottini JP, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001;44:364-373.
  • 21. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators in colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986;57:1866-1870.
  • 22. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vasculer endothelial growth factor as prognostic factors in node negative colon cancer. Arch Surg 1997;132: 541-546.
  • 23. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O'Malley FP. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996; 20:1260- 1265.
There are 23 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Deniz Durak This is me

Asım Cingi This is me

Manuk Manukyan This is me

Handan Kaya This is me

Ahmet Aktan This is me

Cumhur Yeğen

Publication Date June 29, 2015
Published in Issue Year 2005 Volume: 18 Issue: 2

Cite

APA Durak, D., Cingi, A., Manukyan, M., Kaya, H., et al. (2015). KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ. Marmara Medical Journal, 18(2), 53-58.
AMA Durak D, Cingi A, Manukyan M, Kaya H, Aktan A, Yeğen C. KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ. Marmara Med J. August 2015;18(2):53-58.
Chicago Durak, Deniz, Asım Cingi, Manuk Manukyan, Handan Kaya, Ahmet Aktan, and Cumhur Yeğen. “KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ”. Marmara Medical Journal 18, no. 2 (August 2015): 53-58.
EndNote Durak D, Cingi A, Manukyan M, Kaya H, Aktan A, Yeğen C (August 1, 2015) KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ. Marmara Medical Journal 18 2 53–58.
IEEE D. Durak, A. Cingi, M. Manukyan, H. Kaya, A. Aktan, and C. Yeğen, “KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ”, Marmara Med J, vol. 18, no. 2, pp. 53–58, 2015.
ISNAD Durak, Deniz et al. “KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ”. Marmara Medical Journal 18/2 (August 2015), 53-58.
JAMA Durak D, Cingi A, Manukyan M, Kaya H, Aktan A, Yeğen C. KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ. Marmara Med J. 2015;18:53–58.
MLA Durak, Deniz et al. “KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ”. Marmara Medical Journal, vol. 18, no. 2, 2015, pp. 53-58.
Vancouver Durak D, Cingi A, Manukyan M, Kaya H, Aktan A, Yeğen C. KOLO-REKTAL KANSERLERDE VASKÜLER ENDOTELİAL BÜYÜME FAKTÖRÜ (VEBF) EKSPRESYONUNUN PROGNOZ ÜZERİNE ETKİSİ. Marmara Med J. 2015;18(2):53-8.